Specifically, in mice injected with Lv-shIFITM3-KG1a cells, the downregulation of IFITM3 expression led to a significant reduction in the expression levels of AML-associated immunological markers CD11b, CD33, and CD123. The gene discussed is CD33; the disease is acute myeloid leukemia.